Acquisitions (Details Narrative) - USD ($)				12 Months Ended
	Nov. 04, 2019	Apr. 23, 2019	Apr. 22, 2019	Dec. 31, 2019	Dec. 31, 2018	Apr. 21, 2019
Common stock, par value				$ 0.01	$ 0.01
Common stock, shares issued				84,069,967	6,843,802
Common stock, shares outstanding				84,069,967	6,843,802
Number of preferred stock for acquisitions, value					$ 819,191
Shareholders [Member]
Common stock, shares outstanding						41,419,934
Equity ownership percentage			15.00%
Stock price			$ 0.09
Common Stock [Member]
Conversion of shares				80,772
Shares issued during the period				20,750	60,000
Number of preferred stock for acquisitions					204,796
Number of preferred stock for acquisitions, value					$ 2,048
Merger Agreement [Member]
Conversion of shares			10,318,746
Common stock, shares issued		82,419,967	41,419,934
Common stock, shares outstanding		82,419,967	41,419,934
Merger Agreement [Member] | PointR [Member]
Stock price	$ 0.18
Conversion of stock, value	$ 200,000
Conversion of stock, shares	84,475
Purchase price	$ 17,865,792
Consideration transferred	15,200,000
Contingent consideration	$ 2,600,000
Number of preferred stock for acquisitions	84,475
Number of preferred stock for acquisitions, value	$ 15,000,000
Repayment of short term debt	200,000
Merger Agreement [Member] | Shareholders [Member] | PointR [Member]
Purchase price	17,831,427
Contingent consideration	$ 2,625,000
Merger Agreement [Member] | Security Holders [Member] | PointR [Member]
Equity ownership percentage	23.29%
Merger Agreement [Member] | Stockholders [Member] | PointR [Member]
Equity ownership percentage	76.71%
Merger Agreement [Member] | Contingent Value Right [Member]
Percentage of net proceeds from merger			75.00%
Net proceeds from merger			$ 500,000
Merger Agreement [Member] | Oncotelic [Member]
Conversion of shares			41,000,033
Common stock, shares outstanding			10,318,746
Merger Agreement [Member] | Oncotelic [Member] | Former Shareholders [Member]
Shares to be issued during period preferred stock			10,000
Merger Agreement [Member] | Oncotelic [Member] | Converted Options [Member]
Conversion of shares			3,102,411
Merger Agreement [Member] | Oncotelic [Member] | Converted Warrants [Member]
Conversion of shares			150,000
Merger Agreement [Member] | Series A Preferred Stock [Member]
Conversion of shares			0.01877292
Merger Agreement [Member] | Series A Preferred Stock [Member] | Oncotelic [Member]
Conversion of shares			193,713
Shares issued during the period			77,154
Merger Agreement [Member] | Series A Convertible Preferred Stock [Member]
Conversion of shares			0.01877292
Merger Agreement [Member] | Series A Convertible Preferred Stock [Member] | Oncotelic [Member]
Conversion of shares		193,713	193,713
Shares issued during the period			77,154
Stock issued preferred stock conversion basis		preferred stock which converted at a 1:1,000 ratio
Merger Agreement [Member] | Common Stock [Member]
Common stock, par value			$ 0.01
Conversion of shares		193,712,995	3.97335267
Conversion of shares, par value			$ 0.01
Merger Agreement [Member] | Common Stock [Member] | PointR [Member]
Equity ownership percentage	23.29%
Stock price	$ 0.18
Conversion of stock, shares	1,000
Number of preferred stock for acquisitions	84,474,854
Number of preferred stock for acquisitions, value	$ 15,205,473
Common stock equivalents	$ 360,638,491
Merger Agreement [Member] | Common Stock [Member] | Oncotelic [Member]
Conversion of shares			1,000
Common stock, shares outstanding			7,866,335
Merger Agreement [Member] | Common Stock [Member] | Oncotelic [Member] | Former Shareholders [Member]
Shares issued during the period			2,100,000
Merger Agreement [Member] | Preferred Stock [Member] | PointR [Member]
Conversion of stock, shares	1,000
Contingent consideration	$ 2,600,000
Number of preferred stock for acquisitions	84,475